A retrospective post hoc analysis of the prospective RISE/RIDE studies, which included 666 DME patients treated with intravitreal ranibizumab or sham, revealed that despite all groups showed a rise in the percentage of patients with progressive posterior CNP from baseline to month 24, the progression was significantly quicker in the sham group at every time point between months 3 and 24, indicating that patients with DME may benefit from monthly anti-VEGF injections to delay the progression of retinal ischemia (64). Here, VEGFA is linked to retinal ischemia.